Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York. Effective as of December 31, 2019, Avenue Therapeutics, Inc. operates as a subsidiary of InvaGen Pharmaceuticals, Inc.
Website: avenuetx.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of -$0.24 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -2 874.5% (LTM)

Entry Point: Share price is 0.0% higher than minimum and 99.9% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: ATXI
Share price, USD:  (-29.6%)0.0943
year average price 0.5620  


year start price 0.9500 2023-04-27

max close price 1.2100 2023-07-13

min close price 0.0943 2024-04-24

current price 0.0943 2024-04-25
Common stocks: 1 475 650

Dividend Yield:  0.0%
Last revenue growth (y/y):  0.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  0.0%
Historical growth of EBITDA:  ---
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 0
Net Debt ($m): -1
EV (Enterprise Value): -1
Price to Book: 0.1x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-11-29InvestorPlace

Why Is Avenue Therapeutics (ATXI) Stock Up 59% Today?

2023-04-27GlobeNewsWire

Avenue Therapeutics to Present at Aegis Capital Virtual Conference
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol ATXI ATXI ATXI ATXI ATXI ATXI ATXI
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-18 2023-11-13 2023-08-11 2023-05-12 2023-03-31 2022-11-10 2022-08-15
acceptedDate 2024-03-18 16:15:34 2023-11-13 16:15:46 2023-08-11 16:25:06 2023-05-12 16:15:49 2023-03-31 16:18:24 2022-11-10 16:33:15 2022-08-15 17:13:01
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
revenue 0 0 0 0 0 0 0
costOfRevenue 0 0 0 0 0 0 0
grossProfit 0 0 0 0 0 0 0
grossProfitRatio 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 982 000 907 000 3M 5M 545 000 194 000 151 000
generalAndAdministrativeExpenses 1M 1M 896 000 984 000 3M 469 000 454 000
sellingAndMarketingExpenses 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 1M 1M 896 000 984 000 3M 469 000 454 000
otherExpenses 0 0 0 0 0 0 0
operatingExpenses 2M 2M 4M 6M 4M 663 000 605 000
costAndExpenses 2M 2M 4M 6M 4M 663 000 0
interestIncome 22 000 9000.000 57 000 37 000 16 000 1000.000 1000.000
interestExpense 0 0 0 332 000 -4M 1000.000 0
depreciationAndAmortization 2119.000 2068.000 57 000 37 000 6M 0 0
ebitda -2M -2M -4M -6M 2M -663 000 -604 000
ebitdaratio 0 0 0 0 0 0 0
operatingIncome -2M -2M -4M -6M -4M -663 000 -605 000
operatingIncomeRatio 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet 3M 3M -150 000 -1M 4M 1000.000 1000.000
incomeBeforeTax 617 000 526 000 -4M -8M 524 000 -662 000 -604 000
incomeBeforeTaxRatio 0 0 0 0 0 0 0
incomeTaxExpense -23 000 -2068.000 -66 000 1M -4M -2000.000 0
netIncome 640 000 526 000 -4M -9M 5M -660 000 -604 000
netIncomeRatio 0 0 0 0 0 0 0
eps 0.025 0.065 -1.290 -3.910 2.290 -0.450 -0.413
epsdiluted 0.025 0.065 -1.290 -3.910 2.290 -0.450 -0.413
weightedAverageShsOut 26M 8M 3M 2M 2M 1M 1M
weightedAverageShsOutDil 26M 8M 3M 2M 2M 1M 1M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol ATXI ATXI ATXI ATXI ATXI ATXI ATXI
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-18 2023-11-13 2023-08-11 2023-05-12 2023-03-31 2022-11-10 2022-08-15
acceptedDate 2024-03-18 16:15:34 2023-11-13 16:15:46 2023-08-11 16:25:06 2023-05-12 16:15:49 2023-03-31 16:18:24 2022-11-10 16:33:15 2022-08-15 17:13:01
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 2M 161 000 2M 8M 7M 217 000 890 000
shortTermInvestments 0 0 0 0 0 0 0
cashAndShortTermInvestments 2M 161 000 2M 8M 7M 217 000 890 000
netReceivables 0 13 000 26 000 13 000 0 0 0
inventory 0 310 000 0 0 0 0 0
otherCurrentAssets 67 000 18 000 69 000 198 000 137 000 358 000 0
totalCurrentAssets 2M 502 000 2M 8M 7M 575 000 890 000
propertyPlantEquipmentNet 0 0 0 0 0 0 0
goodwill 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0
otherNonCurrentAssets 0 310 000 0 0 137 000 0 0
totalNonCurrentAssets 0 310 000 0 0 137 000 0 0
otherAssets 0 -310 000 95 000 211 000 -137 000 358 000 115 000
totalAssets 2M 502 000 2M 8M 7M 575 000 1M
accountPayables 401 000 1M 446 000 2M 150 000 405 000 397 000
shortTermDebt 0 0 0 0 0 0 0
taxPayables 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0
otherCurrentLiabilities 795 000 4M 7M 9M 3M 209 000 10000.000
totalCurrentLiabilities 1M 5M 8M 11M 4M 614 000 407 000
longTermDebt 0 0 0 0 0 0 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 0 2M 949 000 -405 000 0
totalNonCurrentLiabilities 0 0 0 2M 949 000 405 000 0
otherLiabilities 0 0 0 -2M -949 000 -405 000 0
capitalLeaseObligations 0 0 0 0 0 0 0
totalLiabilities 1M 5M 8M 11M 4M 614 000 407 000
preferredStock 0 0 0 0 0 0 0
commonStock 3000.000 1000.000 1000.000 1000.000 0 0 2000.000
retainedEarnings -91M -92M -92M -88M -81M -81M -80M
accumulatedOtherComprehensiveIncomeLoss -0.000 0 0 0 0 0 0
othertotalStockholdersEquity 93M 88M 87M 87M 84M 81M 81M
totalStockholdersEquity 2M -4M -5M -1M 4M -39 000 598 000
totalEquity 654 000 -5M -6M -2M 4M -39 000 598 000
totalLiabilitiesAndStockholdersEquity 2M 502 000 2M 8M 7M 575 000 1M
minorityInterest -928 000 -872 000 -810 000 -705 000 -639 000 0 0
totalLiabilitiesAndTotalEquity 2M 502 000 2M 8M 7M 575 000 1M
totalInvestments 0 0 0 0 0 0 0
totalDebt 0 0 0 0 0 0 0
netDebt -2M -161 000 -2M -8M -7M -217 000 -890 000
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol ATXI ATXI ATXI ATXI ATXI ATXI ATXI
reportedCurrency USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-03-18 2023-11-13 2023-08-11 2023-05-12 2023-03-31 2022-11-10 2022-08-15
acceptedDate 2024-03-18 16:15:34 2023-11-13 16:15:46 2023-08-11 16:25:06 2023-05-12 16:15:49 2023-03-31 16:18:24 2022-11-10 16:33:15 2022-08-15 17:13:01
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3 Q2
netIncome 640 000 513 000 -4M -8M 524 000 -662 000 -604 000
depreciationAndAmortization 0 0 0 0 0 0 0
deferredIncomeTax 0 0 0 0 0 0 0
stockBasedCompensation 307 000 561 000 27 000 11 000 12 000 25 000 43 000
changeInWorkingCapital -911 000 -391 000 -3M 4M 345 000 83 000 -382 000
accountsReceivables 13 000 13 000 -13 000 0 0 0 0
inventory 0 -1 000 000 13 000 0 0 0 0
accountsPayables -1M 784 000 -942 000 912 000 385 000 0 -54 000
otherWorkingCapital 190 000 -188 000 -2M 3M -40 000 0 0
otherNonCashItems -2M -2M 2M 2M -5M 0 0
netCashProvidedByOperatingActivities -2M -889 000 -5M -2M -4M -554 000 -943 000
investmentsInPropertyPlantAndEquipment 3M -1 000 000 -2M 0 0 0 0
acquisitionsNet 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0
otherInvestingActivites -3M 0 0 0 0 0 0
netCashUsedForInvestingActivites 0 -1 000 000 -2M 0 0 0 0
debtRepayment 0 0 0 0 0 0 0
commonStockIssued 4M 550 000 0 3M 12M 0 0
commonStockRepurchased 0 0 0 1M -1M 0 0
dividendsPaid 0 0 0 0 0 0 0
otherFinancingActivites 71 000 -71 000 0 -1M -241 000 0 0
netCashUsedProvidedByFinancingActivities 4M 479 000 0 3M 11M 0 0
effectOfForexChangesOnCash 0 2M 0 0 0 0 0
netChangeInCash 2M -1M -7M 2M 6M -673 000 -943 000
cashAtEndOfPeriod 2M 161 000 2M 8M 7M 217 000 890 000
cashAtBeginningOfPeriod 161 000 2M 8M 7M 217 000 890 000 2M
operatingCashFlow -2M -889 000 -5M -2M -4M -554 000 -943 000
capitalExpenditure 3M -1 000 000 -2M 0 0 0 0
freeCashFlow 676 000 -2M -7M -2M -4M -554 000 -943 000
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-02-22 13:30 ET
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
2024-02-02 19:40 ET
Lindsay Rosenwald’s Fortress Bio (NASDAQ: FBIO) Spotlight on 2024 Milestones from Subsidiaries
2024-01-11 13:00 ET
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
2024-01-05 14:15 ET
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
2024-01-04 13:30 ET
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
2024-01-02 13:30 ET
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
2023-12-01 13:30 ET
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
2023-11-13 21:05 ET
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
2023-11-02 19:00 ET
Avenue Therapeutics Announces Closing of $5.0 Million Public Offering
2023-10-31 13:15 ET
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
2023-09-05 12:30 ET
Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
2023-08-10 20:15 ET
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
2023-08-01 12:30 ET
Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study
2023-07-27 12:30 ET
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
2023-07-25 12:30 ET
Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol
2023-05-12 12:30 ET
Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
2023-04-27 12:30 ET
Avenue Therapeutics to Present at Aegis Capital Virtual Conference
2023-04-17 20:01 ET
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol
2023-03-30 20:01 ET
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights
2023-03-10 11:00 ET
AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's Disease
2023-03-08 21:01 ET
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates
2023-03-02 13:00 ET
Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular Atrophy
2023-01-31 18:30 ET
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI)
2023-01-31 18:09 ET
Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement
2023-01-27 16:58 ET
Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
2022-11-10 21:10 ET
Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
2022-11-08 13:30 ET
Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders
2022-10-12 14:25 ET
Aegis Capital Corp. Acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI)
2022-10-11 18:15 ET
Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering
2022-10-07 03:00 ET
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
2022-09-22 20:25 ET
Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA
2022-02-16 03:00 ET
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol
2022-02-15 12:05 ET
Avenue Therapeutics Stock Trading Halted Today
2021-12-15 19:15 ET
Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)
2021-12-15 17:00 ET
Avenue Therapeutics Announces Closing of Public Offering of Common Stock
2021-12-13 01:00 ET
Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock
2021-11-29 13:00 ET
Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA Tentatively Scheduled for February 15, 2022
2021-11-17 14:30 ET
Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option
2021-11-12 15:40 ET
Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)
2021-11-12 14:20 ET
Avenue Therapeutics Announces Closing of Public Offering of Common Stock
2021-11-10 02:30 ET
Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock
2021-10-25 11:00 ET
Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs
2021-06-14 11:00 ET
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
2021-04-13 10:30 ET
Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol
2020-12-18 13:00 ET
Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis
2020-12-18 13:00 ET
Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network
2020-12-17 12:00 ET
Avenue Therapeutics Provides Regulatory Update for IV Tramadol
2020-10-12 10:30 ET
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
2020-09-09 12:00 ET
Avenue Therapeutics Announces Publication of a Review of IV Tramadol
2020-08-14 11:30 ET
Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
2020-07-21 12:30 ET
Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results
2020-06-05 12:30 ET
Avenue Therapeutics Announces Publications in Peer-Reviewed Journals
2020-05-29 12:30 ET
Avenue Therapeutics to Host Virtual Annual Meeting of Stockholders
2020-05-11 11:30 ET
Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
2020-04-23 12:30 ET
Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters
2020-03-30 11:30 ET
Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights
2020-02-13 13:00 ET
Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA
2019-12-11 13:30 ET
Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol
2019-11-04 12:30 ET
Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
2019-10-28 12:30 ET
Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development
2019-10-18 12:30 ET
Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual Meeting
2019-03-12 11:30 ET
Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights
2019-02-11 12:30 ET
Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary)
2018-12-19 13:00 ET
Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain

SEC forms

Show financial reports only

SEC form 10
2024-03-18 00:00 ET
Avenue Therapeutics reported for 2023 q4
SEC form 8
2024-03-18 00:00 ET
Avenue Therapeutics published news for 2023 q4
SEC form 8
2024-03-18 00:00 ET
Avenue Therapeutics reported for 2023 q4
SEC form 10
2023-11-13 00:00 ET
Avenue Therapeutics reported for 2023 q3
SEC form 8
2023-11-13 00:00 ET
Avenue Therapeutics reported for 2023 q3
SEC form 10
2023-08-11 00:00 ET
Avenue Therapeutics reported for 2023 q2
SEC form 8
2023-08-10 00:00 ET
Avenue Therapeutics reported for 2023 q2
SEC form 10
2023-05-12 00:00 ET
Avenue Therapeutics reported for 2023 q1
SEC form 8
2023-05-12 00:00 ET
Avenue Therapeutics reported for 2023 q1
SEC form 10
2023-03-31 00:00 ET
Avenue Therapeutics reported for 2022 q4
SEC form 8
2023-03-30 00:00 ET
Avenue Therapeutics reported for 2022 q4
SEC form 10
2022-11-10 00:00 ET
Avenue Therapeutics reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
Avenue Therapeutics reported for 2022 q3
SEC form 10
2022-08-15 00:00 ET
Avenue Therapeutics reported for 2022 q2
SEC form 10
2022-05-16 00:00 ET
Avenue Therapeutics reported for 2022 q1
SEC form 10
2022-03-25 00:00 ET
Avenue Therapeutics published news for 2021 q4
SEC form 10
2021-11-15 00:00 ET
Avenue Therapeutics published news for 2021 q3
SEC form 10
2021-08-16 00:00 ET
Avenue Therapeutics published news for 2021 q2
SEC form 10
2021-05-17 00:00 ET
Avenue Therapeutics published news for 2021 q1